ReviewHeart failure reviews2026
Atrial fibrillation and heart failure.
Review in Heart failure reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation and heart failure frequently coexist and interact through shared pathophysiological mechanisms, each condition promoting the onset and progression of the other. This bidirectional relationship is mediated by structural and electrical remodelling, neurohormonal activation, and atrial myocardial disease, resulting in worse clinical outcomes compared with either condition alone. Advances in heart failure–directed medical therapy, rhythm-control strategies—particularly catheter ablation—and device-based monitoring have reshaped contemporary management, while recent trials have challenged traditional approaches to anticoagulation in patients with subclinical atrial arrhythmias. This review synthesizes current evidence on the mechanisms linking atrial fibrillation and heart failure, discusses evolving therapeutic strategies including early rhythm control and device-detected atrial high-rate episodes, and highlights areas of uncertainty and future research. An integrated, patient-centered approach addressing both arrhythmia burden and heart failure substrate is essential to improving outcomes in this complex and growing population.
Indexed as
Identifiers
41741877What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.